Cramer: This stock could quadruple

Results of a clinical trial of a breast cancer drug could make this company a takeover target, too, says CNBC's Jim Cramer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.